Advertisement
Advertisement
U.S. markets open in 4 hours 33 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Theralase Technologies Inc. (TLTFF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1815+0.0089 (+5.16%)
At close: 03:44PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.1726
Open0.1712
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1712 - 0.1891
52 Week Range0.1200 - 0.2600
Volume248,326
Avg. Volume89,508
Market Cap37.076M
Beta (5Y Monthly)1.92
PE Ratio (TTM)N/A
EPS (TTM)-0.0170
Earnings DateNov 29, 2021 - Dec 03, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for TLTFF

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • THERALASE TECHNOLOGIES INC
    ORGO: What does Argus have to say about ORGO?ORGANOGENESIS HOLDINGS INC has an Investment Rating of HOLD; a target price of $11.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of High.
    Rating
    Fair Value
    Economic Moat
    6 days agoArgus Research
View more
  • GlobeNewswire

    Theralase Releases 3Q21 Financial Statements and Newsletter

    TORONTO, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated compounds and their associated drug formulations with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses has released the Company’s unaudited 3Q2021 condensed interim consolidated Financial

  • GlobeNewswire

    Theralase Announces Leadership Reorganization

    TORONTO, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDC”) and associated drug formulations, announced today the following leadership reorganization: Effective November 15, 2021, Dr. Arkady Mandel, M.D., Ph.D., D.Sc., who is currently the Chief Scientific Officer (“CSO”) of the Company, will a

  • Simply Wall St.

    We're Hopeful That Theralase Technologies (CVE:TLT) Will Use Its Cash Wisely

    Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Advertisement
Advertisement